Getinge and 908 Devices Partner to Enhance Bioreactor Capabilities for Continuous Monitoring of Key Cell Culture Parameters
19 December 2024 - 11:00PM
Business Wire
Today, 908 Devices Inc. (Nasdaq: MASS) and Getinge announce
their collaboration to integrate Getinge’s bioreactors with 908
Devices’ MAVEN for automated control of glucose and lactate levels
in cell cultures. The combined solution will help scientists
measure critical process parameters in bioreactors, offering
continuous, real-time analysis without the need for manual
sampling.
In the field of bioprocessing, the continuous monitoring of
glucose and lactate levels is crucial for optimizing cell culture
conditions and thereby the research and development of
biopharmaceutical products. Accurate measurement of these
parameters allows for better control of the bioreactor environment,
leading to improved productivity and reduced time to market.
908 Devices’ MAVEN provides highly precise, on-line monitoring
and control of glucose and lactate without any loss of bioreactor
volume, enabling biopharma scientists to maintain optimal nutrient
and metabolite concentrations, even at very low levels. Data from
MAVEN is collected and supervised through Getinge’s advanced
controllers. It can set up control loops, recipe functionality and
advanced control, and has the capacity to measure from up to two
bioreactors simultaneously.
“We are thrilled to collaborate with 908 Devices on this joint
solution to make our customers’ life in the lab easier. This means
continuous visibility into concentration changes, continuous
control of glucose levels, and the ability to adjust control
strategies based on real-time measurements, such as starting
feeding or stopping cultivation. This enables our customers to
increase productivity and go faster to market,” explains Timo
Keijzer, Director Product Marketing at Getinge.
Timo’s emphasis on seamless lab workflows is echoed by
Christopher D. Brown, Chief Product Officer and Co-founder at 908
Devices, who adds: “We’re excited to partner with Getinge as we
share a mutual passion to enable our biopharma customers with
modern bioprocess automation tools for control of critical process
parameters, thereby increasing their process understanding and
accelerating development workflows. In addition, implementing
robust control strategies in development optimizes product
performance and facilitates a scalable process.”
The MAVEN device will be compatible with Getinge’s Livit Flex
controller and connected through Livit Links sensor ports. Find out
more about Getinge’s bioreactors.
About Getinge
With a firm belief that every person and community should have
access to the best possible care, Getinge provides hospitals and
life science institutions with products and solutions that aim to
improve clinical results and optimize workflows. The offering
includes products and solutions for intensive care, cardiovascular
procedures, operating rooms, sterile reprocessing and life science.
Getinge employs approximately 12,000 people worldwide and the
products are sold in more than 135 countries.
About 908 Devices
908 Devices is revolutionizing chemical analysis with its simple
handheld and desktop devices, addressing life-altering
applications. The Company’s devices are used at the point-of-need
to interrogate unknown and invisible materials and provide quick,
actionable answers to directly address some of the most critical
problems in bioprocessing, pharma/biopharma, forensics, life
sciences research and adjacent markets. The Company is
headquartered in the heart of Boston, where it designs and
manufactures innovative products that bring together the power of
complementary analytical technologies, microfluidic sampling and
separations, software automation, and machine learning.
Forward Looking Statements for 908 Devices
This press release includes “forward looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements other than statements of historical facts are
forward-looking statements, including, without limitation,
statements regarding the expected uses and capabilities of the
Company’s products. Words such as “may,” “will,” “expect,” “plan,”
“anticipate,” “estimate,” “intend” and similar expressions (as well
as other words or expressions referencing future events, conditions
or circumstances) are intended to identify forward-looking
statements. These forward-looking statements are based on
management’s current expectations and involve known and unknown
risks, uncertainties and assumptions which may cause actual results
to differ materially from any results expressed or implied by any
forward-looking statement, including the risks outlined under “Risk
Factors” and elsewhere in the Company’s filings with the Securities
and Exchange Commission which are available on the SEC's website at
www.sec.gov. Additional information will be made available in our
annual and quarterly reports and other filings that we make from
time to time with the SEC. Although the Company believes that the
expectations reflected in its forward-looking statements are
reasonable, it cannot guarantee future results. The Company has no
obligation, and does not undertake any obligation, to update or
revise any forward-looking statement made in this press release to
reflect changes since the date of this press release, except as may
be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241219224577/en/
Media Contact for 908 Devices Barbara Russo
brusso@908devices.com
Investor Contact for 908 Devices Carrie Mendivil
IR@908devices.com
908 Devices (NASDAQ:MASS)
Historical Stock Chart
From Nov 2024 to Dec 2024
908 Devices (NASDAQ:MASS)
Historical Stock Chart
From Dec 2023 to Dec 2024